Agents that promote or maintain histone acetylation through HDAC inhibition and/or HAT stimulation may help to lower colon adenoma/carcinoma incidence, especially in high-risk families, or could be included in therapeutic protocols to treat advanced colon cancer. The gene discussed is TMPRSS11D; the disease is colonic neoplasm.